Clinical Trials Logo

Leukemia, Plasma Cell clinical trials

View clinical trials related to Leukemia, Plasma Cell.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01658904 Terminated - Multiple Myeloma Clinical Trials

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Background: - Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant. To make this treatment more effective, researchers want to give another drug along with the transplant. This drug, carfilzomib, is often used to help treat plasma cell myeloma. However, it is not usually given along with the transplant. Researchers want to see if it is safe and effective to combine the stem cell transplant with carfilzomib, and if it improves the results of the transplant. Objectives: - To test the safety and effectiveness of carfilzomib given with stem cell transplant for plasma cell myeloma. Eligibility: - Individuals between 18 and 75 years of age who are having a stem cell transplant to treat plasma cell myeloma. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and a bone marrow biopsy will also be performed. - Participants will have their own stem cells collected for the transplant. The transplant will be performed according to the standard of care. - All participants will receive carfilzomib on the first 2 days after transplant. The study doctors will determine the number of additional doses that they may have. - Treatment will be monitored with frequent blood tests and imaging studies.

NCT ID: NCT00615589 Terminated - Multiple Myeloma Clinical Trials

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Start date: February 2008
Phase: Phase 2
Study type: Interventional

Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are transplanted back into their body. Patients with multiple myeloma and high risk genes, always relapse after an autologous transplant and often die within two years from the time of their transplant. A different type of transplant allogeneic) using donor cells, may work better for high-risk Multiple Myeloma, because the donor cells may help kill the lymphoid cancer cells. This study will investigate if a matched donor stem cell transplant using a newer, reduced toxicity, chemotherapy (Flu-Bu4) is a feasible option for patients with high risk, Multiple Myeloma.